Hosted on MSN6d
MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study
The AAV-GAD bridging study met the primary endpoint of safety and tolerability, and showed early promise in Parkinson’s ...
FierceBiotech8d
MeiraGTx's gene therapy improves motor function and quality of life in phase 2 Parkinson's trial
MeiraGTx is looking to march its Parkinson’s disease treatment forward into phase 3 after the gene therapy improved motor ...
pharmaphorum7d
MeiraGTx plans to take Parkinson's gene therapy into phase 3
According to MeiraGTx, AAV-GAD is designed to reprogramme dysfunctional circuits in the Parkinson's brain through the local ...
Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints
MeiraGTx's clinical study of AAV-GAD for Parkinson's disease showed significant improvements in motor function and quality of ...
MeiraGTx gains as gene therapy shows promise in Parkinson’s
MeiraGTx Holdings (MGTX) stock gains in premarket trading after positive trial results for the company's AAV-GAD gene therapy ...
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
The primary study objective of safety and tolerability was metSignificant and clinically meaningful improvements from baseline demonstrated for ...
MeiraGTx Reports Positive AAV-GAD Trial Data For Parkinson's Disease; Stock Climbs
MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical-stage genetic medicines company, announced Tuesday positive top-line ...
MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings
Exciting results for MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease, with promising phase 1/2 data and ...
Yahoo Finance6d
MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study
A Phase I/II trial (NCT05603312) with MeiraGTx's AAV-GAD Parkinson’s disease gene therapy has met its primary endpoint. The sham-controlled bridging study evaluated the company's AAV-GAD therapy ...
KTLA8d
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
MGT-GAD-025 is a 6-month, three-arm, randomized, double-blind, sham-controlled study using AAV-GAD drug product manufactured by MeiraGTx at its wholly-owned facilities with its commercial platform ...